Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Acute Repetitive Seizures Market

Acute Repetitive Seizures Market Share

Report ID: GMI11873
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Acute Repetitive Seizures Market Share

The acute repetitive seizures industry is increasingly dynamic, driven by both established pharmaceutical companies and emerging biopharmaceutical firms. This competitive edge is further enhanced by ongoing research and development efforts aimed at introducing novel therapies that address unmet medical needs. The market is also witnessing collaborations and partnerships between companies and healthcare providers to enhance the delivery and effectiveness of seizure management solutions.

Acute Repetitive Seizures Market Companies

Prominent players operating in the acute repetitive seizures industry include:

AdvaCare Pharma Limited
Aquestive Therapeutics
Bausch Health Companies
Lupin Limited
Neuracle Lifesciences
Neurelis
Pfizer
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries
UCB S.A.
Veriton Pharma

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for acute repetitive seizures was valued at USD 2.7 billion in 2023 and is expected to reach USD 7.7 billion by 2032, driven by a CAGR of 12.4% from 2024 to 2032, primarily due to the increasing prevalence of epilepsy and advancements in rescue therapies.

The intranasal segment was valued at USD 1.2 billion in 2023, driven by its non-invasive, convenient, and rapid drug delivery method essential for managing seizure emergencies.

The North America market was valued at USD 1.1 billion in 2023, driven by the high prevalence of epilepsy and a robust healthcare infrastructure that facilitates timely diagnosis and management.

Prominent players in the industry include AdvaCare Pharma Limited, Aquestive Therapeutics, Bausch Health Companies, Lupin Limited, Neuracle Lifesciences, Neurelis, and Pfizer, driven by their continuous development of novel rescue medications.